Your shopping cart is currently empty

JNJ28871063 hydrochloride is an orally active, ATP-competitive, and highly selective pan-ErbB kinase inhibitor with IC50 values of 22 nM for ErbB1, 38 nM for ErbB2, and 21 nM for ErbB4, JNJ28871063 hydrochloride effectively inhibits phosphorylation of key tyrosine residues in EGFR and ErbB2, crossing the blood–brain barrier, and demonstrating antitumor efficacy in xenograft models overexpressing EGFR and ErbB2.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $93 | - | In Stock | |
| 5 mg | $228 | - | In Stock | |
| 10 mg | $372 | - | In Stock | |
| 25 mg | $762 | - | In Stock | |
| 50 mg | $1,320 | - | In Stock | |
| 100 mg | $2,120 | - | In Stock |
| Description | JNJ28871063 hydrochloride is an orally active, ATP-competitive, and highly selective pan-ErbB kinase inhibitor with IC50 values of 22 nM for ErbB1, 38 nM for ErbB2, and 21 nM for ErbB4, JNJ28871063 hydrochloride effectively inhibits phosphorylation of key tyrosine residues in EGFR and ErbB2, crossing the blood–brain barrier, and demonstrating antitumor efficacy in xenograft models overexpressing EGFR and ErbB2. |
| Targets&IC50 | HER2:38 nM, Her1:22 nM |
| In vitro | In kinase assays, JNJ28871063 hydrochloride inhibited ErbB1, ErbB2, and ErbB4 with IC50 values of 22-38 nM. In cellular assays, it demonstrated growth inhibition in ErbB-overexpressing cancer cells (IC50 60-168 nM) while showing low potency in low-expression lines (>10 μM). Treatment (3 μM, 16 h) reduced basal ErbB2 phosphorylation in BT474 and SKBR3 cells [1]. |
| In vivo | In nude mice bearing N87 (gastric cancer) xenografts, oral administration of JNJ28871063 hydrochloride (100 mg/kg/day for 30 days) resulted in a tumor growth inhibition (TGI) of 71%. In an A431 (epidermoid carcinoma) xenograft model, the same dosage produced a TGI of 66.8%. A characteristic of the compound is its ability to cross the blood-brain barrier (BBB), demonstrating activity against intracranial tumors in preclinical models of ErbB-driven cancers [1]. |
| Synonyms | JNJ-28871063 hydrochloride, JNJ 28871063 hydrochloride |
| Molecular Weight | 519.42 |
| Formula | C24H28Cl2N6O3 |
| Cas No. | 944342-90-9 |
| Smiles | N(C=1C(/C=N/OCCN2CCOCC2)=C(N)N=CN1)C3=CC(Cl)=C(OCC4=CC=CC=C4)C=C3.Cl |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (154.02 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (1.93 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.